Next-Generation Sequencing Services Market

The next-generation sequencing services market is anticipated to reach USD 8.77 billion in 2030 from USD 3.80 billion in 2025, with a significant CAGR of 18.2%. Major growth drivers of the next-generation sequencing services market are the rising adoption of genomics in precision medicine and increasing investment in genomics initiatives.

The next-generation sequencing services market is consolidated. Prominent players in the next-generation sequencing services market are Eurofins Scientific (Luxembourg), Wuxi Biologics (China), BGI Group (China), Macrogen, Inc. (South Korea), among others.  

• In January 2024, Illumina expanded its collaboration with Janssen Research & Development to advance a whole-genome, ctDNA-based molecular residual disease (MRD) assay, strengthening Illumina’s position in oncology NGS services and enabling more sensitive monitoring of treatment response and relapse in clinical studies.
• In June 2024, Eurofins Genomics, part of Eurofins Scientific, was selected to provide large-scale genotyping services for up to five million participants in the UK ‘Our Future Health’ programme, establishing a dedicated laboratory and leveraging high-throughput genotyping and NGS capabilities to support population-level risk prediction and biomarker discovery.

To know about the assumptions considered for the study download the pdf brochure

Illumina, Inc. is a major company in the NGS Services market, primarily due to its solutions being offered to service labs and in-house sequencing teams to support them in delivering high-quality runs. Illumina solutions include whole-genome, whole-exome, targeted panels, and RNA sequencing, including solutions for research programs and those in clinical pipelines. Illumina's service solutions combine library preparation, sequencing, and analysis solutions to enable labs to move from samples to insights more quickly. Cloud and accelerated bioinformatics solutions, such as DRAGEN and Illumina Connected Analytics, have gained broad adoption across the industry, enabling better alignment of data analysis, variant analysis, and reporting. Such solutions will allow customers to scale their presence in oncology research, rare diseases, reproductive and population health, with less need to invest in in-house bioinformatics capabilities.

Eurofins Scientific is among the major players in the market for next-generation sequencing service providers. Eurofins provides end-to-end sequencing service support for translational and research customers seeking scalable capacity without the need to establish it within their organization. Eurofins focuses on delivering a combination of these services: whole genome sequencing, whole exome sequencing, targeted NGS panels, RNA sequencing, and metagenomics sequencing, with QC and library prep for samples. The firm provides these services through its global network of analytical laboratories, with project service support available, which can include assistance in study design, RNAi feasibility and other methodologies, and project processing time. Eurofins Scientific buys these customers the additional performance capabilities of both bioinformatics analysis and data delivery in a single step, in their function, which enables them to transform unassembled read information into meaningful output in any of these focused themes: Oncology research, rare diseases research, Infectious diseases research, Reproductive health research, and Population genomic studies.

BGI Group is a significant player in the next-generation sequencing services market, offering large-scale sequencing and analysis to research, clinical, and biopharmaceutical clients across over 100 countries. They provide support in developing a broad array of service offerings, including whole-genome sequencing, whole-exome sequencing, targeted sequencing panels, RNA sequencing, metagenomics, and single-cell analysis, with high-throughput lab operations optimized for handling large numbers of samples. Their service offerings achieve this through an end-to-end sequencing and analysis workflow that incorporates processing, library prep, sequencing, and analysis, including delivery format based on project requirements. They can thus scale their programs in population genomics, oncology research, rare disease research, reproductive and maternal health, and infectious diseases without developing additional in-house capacity through expansion or building new facilities.

Market Ranking

The next-generation sequencing services market is quite competitive. Large global players dominate a majority of high-end sequencing requirements, with a tail of local and specialized labs differentiating based on turnaround time, depth of analysis, cost, and the ability to deliver clinically relevant reports. The industry is driven by increasing work in oncology, rare diseases, reproductive and infectious diseases, population genomics studies, and an increased need for end-to-end sequencing with bioinformatics analysis. Illumina leads in this next-generation sequencing services market, with a majority of global sequencing capacity driven by Illumina technology solutions, including platforms, consumables, and analysis solutions. A majority of service labs globally follow Illumina solutions for whole-genome, whole-exome, targeted analysis panels, and RNA sequencing analysis. Eurofins Scientific is another major player in the next-generation sequencing services market, boasting an extensive lab network and capabilities in both regulated and research environments. BGI Group is a major provider of high-end sequencing services on this scale, recognized for handling massive samples and projects with speed, scale, and cost-effectiveness. In the future, competition among these firms is increasingly focused on end-to-end delivery capabilities (from sample to report with low turnaround times), enhanced analysis layers with solid bioinformatics capabilities, and efficient support for large, repeat sequencing projects with predictable turnaround times and deliverables.  

Related Reports:

Next-generation Sequencing Services by Type (Sequencing, Presequencing, Bioinformatics, Platform Services), Workflow (Sequencing, Data Analysis), Application (Drug Discovery, Diagnostic, Agriculture), End User (Academia, Pharma Biotech) - Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com